Policy Regulations - The new regulation, effective from July 1, 2023, mandates that any traditional Chinese medicine (TCM) with "unclear" labels in contraindications, adverse reactions, or precautions will not be re-registered after three years [3][4] - The regulation aims to enhance the management of TCM throughout its lifecycle, requiring holders to monitor and evaluate safety risks and update labels accordingly [3][4] Market Situation - Despite the impending deadline, some commonly used TCMs still carry "unclear" labels, indicating a need for compliance [5][6] - A survey of pharmacies revealed that several TCM products, including those from well-known brands, still have safety information marked as "unclear" [6][7] Industry Response - Pharmaceutical companies are actively working to revise their product labels in compliance with the new regulations, with many already completing updates for core products [9] - Companies like Rongchang Pharmaceutical and Yiling Pharmaceutical have reported that they are updating their product information to eliminate "unclear" labels and enhance consumer understanding [9] Industry Outlook - The new regulation is seen as a necessary shift from quantity expansion to quality prioritization in the TCM industry, promoting safer medication practices [10] - The implementation of this policy is expected to phase out low-quality products lacking safety data, thereby concentrating resources on higher-quality enterprises and products [10]

Core Viewpoint - The implementation of the new regulations on traditional Chinese medicine (TCM) product labeling aims to eliminate the "unclear" status in safety information, enhancing the quality and safety of TCM products in the market [1][2][13]. Regulatory Changes - The new regulations, effective from July 1, 2023, require TCM product holders to manage the entire lifecycle of their products and improve the safety information in their labeling, specifically regarding contraindications, adverse reactions, and precautions [1][2]. - By July 1, 2026, any TCM product with "unclear" safety information will not be eligible for re-registration, emphasizing the urgency for companies to update their product labels [1][2]. Industry Response - Many pharmaceutical companies have begun revising their product labels to comply with the new regulations. For instance, companies like Rongchang Pharmaceutical and Yiling Pharmaceutical have completed revisions for their core products, ensuring clear safety information [11][12]. - The industry is adapting by adjusting procurement strategies to focus on compliant products and gradually reducing the inventory of those with high re-registration risks [14]. Market Observations - Despite the new regulations, some commonly used TCM products still display "unclear" safety information, indicating a gap in compliance that needs to be addressed [7][8]. - Reports indicate that TCM accounts for 12% of adverse drug reaction reports, highlighting the need for clearer safety information to mitigate risks associated with TCM usage [7][13]. Future Outlook - The new regulations are expected to promote a shift in the TCM industry from quantity expansion to quality prioritization, ultimately benefiting public health by providing clearer safety guidelines [13][14]. - The elimination of "unclear" labels is anticipated to enhance consumer confidence in TCM products, reducing the risk of unreasonable medication use [14].

Group 1 - Jilin Aodong Pharmaceutical Group actively participated in the "Hundred Enterprises Connect Hundred Villages" initiative, donating essential medicines worth RMB 594,900 to nine poverty alleviation villages in Tibet [1] - The donated medicines include four types of urgently needed common drugs, which will be distributed to 1,147 farming and pastoral households, enhancing local healthcare resources [1] - The company is committed to the development of traditional Chinese medicine (TCM) through innovation and industry upgrades, integrating traditional characteristics with modern elements [1] Group 2 - Jilin Aodong focuses on core research of traditional Chinese medicinal materials, advancing into anti-aging and regenerative medicine, and transitioning TCM from "experience inheritance" to "scientific decoding" [2] - The company has obtained two significant invention patents, upgrading core products to meet high-quality health consumption demands [2] - Jilin Aodong is enhancing the entire TCM industry chain's intelligent upgrade through new production capabilities, utilizing biotechnologies and smart management systems for better quality control [2] Group 3 - The company has secured 525 filing certificates in the TCM granule sector and is leading industry standard research in collaboration with universities, filling market gaps and guiding industry development [3] - Jilin Aodong is reconstructing a health ecosystem centered around deer antler, significantly increasing the knowledge density and value of the entire industry chain [3] - The company aims to drive industry upgrades through technological innovation and standardization, aligning with the "Healthy China" strategy and the 14th Five-Year Plan [3]

Core Viewpoint - The collaboration between Guangxi Shuangyi Pharmaceutical Co., Ltd. and Hubei Jinying Agricultural Development Co., Ltd. aims to enhance the quality and stability of the core raw material, wild chrysanthemum, for Shuangyi's flagship product, Shuangyi Compound Cold Medicine Granules, through standardized planting techniques and a comprehensive supply chain [1][9]. Group 1: Company Collaboration - The visit by Shuangyi's chairman and vice president to Hubei Jinying was focused on exploring the entire supply chain of wild chrysanthemum, including breeding, large-scale cultivation, and processing [1][3]. - Hubei Jinying has established a complete industrial chain for traditional Chinese medicine, with 2,580 acres of medicinal herb cultivation, including 1,030 acres dedicated to wild chrysanthemum [6]. - Shuangyi Pharmaceutical recognizes the advantages of Hubei Jinying's breeding and cultivation techniques, expressing a strong intention to introduce these methods to enhance its own herbal medicine cultivation base [9][11]. Group 2: Product Quality and Market Demand - Wild chrysanthemum is a key ingredient for Shuangyi's products, which include various cold and cough remedies, indicating a significant market demand for this raw material [8]. - The use of Hubei's wild chrysanthemum not only improves the efficacy of Shuangyi's products but also strengthens its competitive edge in the market [9]. - Shuangyi emphasizes its commitment to using authentic medicinal materials, which is crucial for maintaining product quality, especially in light of the recent increase in influenza cases [13]. Group 3: Future Cooperation and Development - The visit established a communication bridge for future collaboration, with both companies aiming to explore new cooperation models that promote resource sharing and complementary advantages [15]. - The partnership is expected to contribute to the high-quality development of the traditional Chinese medicine industry and support rural revitalization efforts [15].

Core Insights - The company reported a total revenue of 2.61 billion yuan in 2024, a decrease of 24.31% compared to 2023, which had a revenue of 3.45 billion yuan [1] - The pharmaceutical sector remains the main revenue driver, contributing 1.88 billion yuan, accounting for 72.11% of total revenue, despite a 27.83% decline from the previous year [1][3] - The company is focusing on key products in its traditional Chinese medicine segment, which includes core products like Anshen Bnna Liquid and Xiaor Chai Gui Oral Liquid, driving significant revenue [3] Revenue Breakdown by Sector - Pharmaceutical revenue: 1,882,395,047.83 yuan (72.11%), down 27.83% from 2,608,458,378.94 yuan [1] - Chain pharmacy wholesale and retail: 391,365,987.46 yuan (14.99%), up 4.36% from 375,020,113.62 yuan [1] - Other business income: 73,862,569.09 yuan (2.83%), up 62.06% from 45,577,260.70 yuan [1] Product Performance - Traditional Chinese medicine sales: 1,605,541,287.90 yuan (61.50%), down 25.42% from 2,152,662,657.59 yuan [1] - Chemical drugs revenue: 276,853,759.93 yuan (10.61%), down 39.26% from 455,795,721.35 yuan [1] - Health products sales reached 2.12 billion yuan, accounting for 8.13% of total revenue [4] Regional Performance - Northeast region: 968,305,996.09 yuan (37.09%), down 14.76% from 1,135,942,714.05 yuan [1] - North region: 377,546,862.16 yuan (14.46%), up 39.78% from 270,101,901.70 yuan [1] - South region: 330,176,089.26 yuan (12.65%), down 20.40% from 414,786,414.20 yuan [1] Sales Strategy and Growth - The company is enhancing its online sales through platforms like JD, Taobao, and Pinduoduo, while also implementing O2O business models in physical stores [4] - The chain pharmacy segment added 183,000 new members, bringing the total to 1.19 million members [3] - The company closed 11 stores and opened 17 new ones, ending the reporting period with a total of 190 stores [3]